MX2007002380A - Produccion de polipeptidos. - Google Patents
Produccion de polipeptidos.Info
- Publication number
- MX2007002380A MX2007002380A MX2007002380A MX2007002380A MX2007002380A MX 2007002380 A MX2007002380 A MX 2007002380A MX 2007002380 A MX2007002380 A MX 2007002380A MX 2007002380 A MX2007002380 A MX 2007002380A MX 2007002380 A MX2007002380 A MX 2007002380A
- Authority
- MX
- Mexico
- Prior art keywords
- cumulative
- culture
- amino acid
- glutamine
- molar
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
- C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/22—Zinc; Zn chelators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se provee un sistema mejorado para la produccion a gran escala de proteinas y/o polipeptidos en cultivo de celulas, en particular, en medios caracterizados por una o mas de: (i) una concentracion acumulada de aminoacidos mayor que aproximadamente 70 mM; (ii) una relacion molar de glutamina acumulada a asparagina acumulada inferior a aproximadamente 2; (iii) una relacion molar de glutamina acumulada a aminoacidos totales acumulados inferior a aproximadamente 0.2; (iv) una relacion molar de ion inorganico acumulado a aminoacidos totales acumulados de entre alrededor de 0.4 y 1; o (v) una concentracion combinada de glutamina acumulada y asparagina acumulada de entre aproximadamente 16 y 36 mM. El uso de dicho sistema permite altos niveles de produccion de proteina, y disminuye la acumulacion de ciertos factores indeseables, tales como amonio y/o lactato. Adicionalmente, se proveen metodos de cultivo que incluyen un cambio de temperatura, que habitualmente comprende una disminucion en la temperatura cuando el cultivo ha alcanzado alrededor de 20%-80% de su densidad celular maxima. Alternativa o adicionalmente, la presente invencion provee metodos tales que, despues de alcanzar un pico, los niveles de lactato y/o amonio en el cultivo disminuyen.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60507404P | 2004-08-27 | 2004-08-27 | |
US60509704P | 2004-08-27 | 2004-08-27 | |
US60494104P | 2004-08-27 | 2004-08-27 | |
PCT/US2005/030437 WO2006026445A1 (en) | 2004-08-27 | 2005-08-26 | Production of polypeptides |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2007002380A true MX2007002380A (es) | 2007-06-15 |
Family
ID=35482353
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2007002380A MX2007002380A (es) | 2004-08-27 | 2005-08-26 | Produccion de polipeptidos. |
Country Status (20)
Country | Link |
---|---|
US (1) | US7294484B2 (es) |
EP (2) | EP1789571B1 (es) |
JP (1) | JP4864892B2 (es) |
KR (2) | KR20110036780A (es) |
CN (2) | CN101048511B (es) |
AR (2) | AR051017A1 (es) |
AU (1) | AU2005280034B2 (es) |
BR (1) | BRPI0514703A (es) |
CA (1) | CA2578141C (es) |
CR (1) | CR8997A (es) |
EC (1) | ECSP077353A (es) |
EG (1) | EG26462A (es) |
ES (1) | ES2628012T3 (es) |
IL (1) | IL181589A0 (es) |
MX (1) | MX2007002380A (es) |
NO (1) | NO342433B1 (es) |
SG (2) | SG190674A1 (es) |
TW (1) | TWI384069B (es) |
WO (1) | WO2006026445A1 (es) |
ZA (1) | ZA200702483B (es) |
Families Citing this family (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2243827B2 (en) | 1996-08-30 | 2017-11-22 | Life Technologies Corporation | Serum-free mammalian cell culture medium, and uses thereof |
US7294484B2 (en) | 2004-08-27 | 2007-11-13 | Wyeth Research Ireland Limited | Production of polypeptides |
US7300773B2 (en) | 2004-08-27 | 2007-11-27 | Wyeth Research Ireland Limited | Production of TNFR-Ig |
US7335491B2 (en) | 2004-08-27 | 2008-02-26 | Wyeth Research Ireland Limited | Production of anti-abeta |
US20060094104A1 (en) | 2004-10-29 | 2006-05-04 | Leopold Grillberger | Animal protein-free media for cultivation of cells |
PT1917276T (pt) * | 2005-08-26 | 2018-06-11 | Ares Trading Sa | Processo para a preparação de interferão beta glicosilado |
AR058140A1 (es) * | 2005-10-24 | 2008-01-23 | Wyeth Corp | Metodo de produccion proteica utilizando compuestos anti-senescencia |
US20070231895A1 (en) * | 2005-11-02 | 2007-10-04 | Lee Gene W | Methods for adapting mammalian cells |
US8604175B2 (en) * | 2005-12-09 | 2013-12-10 | Ares Trading S.A. | Method for purifying FSH or a FSH mutant |
EP3653699A1 (en) | 2006-01-04 | 2020-05-20 | Baxalta Incorporated | Oligopeptide-free cell culture media |
CN101496387B (zh) | 2006-03-06 | 2012-09-05 | 思科技术公司 | 用于移动无线网络中的接入认证的系统和方法 |
PL2495307T3 (pl) * | 2006-07-13 | 2018-07-31 | Wyeth Llc | Wytwarzanie czynnika krzepliwości krwi IX o polepszonym wzorze glikozylacji |
CA2910619A1 (en) | 2006-09-13 | 2008-03-20 | Abbvie Inc. | Cell culture improvements |
US8911964B2 (en) | 2006-09-13 | 2014-12-16 | Abbvie Inc. | Fed-batch method of making human anti-TNF-alpha antibody |
JP5401319B2 (ja) * | 2006-11-03 | 2014-01-29 | ワイス・エルエルシー | 細胞培養における解糖阻害物質 |
CA2668771C (en) * | 2006-11-08 | 2016-03-15 | Wyeth | Rationally designed media for cell culture |
JP5586235B2 (ja) * | 2007-03-02 | 2014-09-10 | ワイス・エルエルシー | ポリペプチドの産生のための細胞培養における銅およびグルタミン酸塩の使用 |
TW200902708A (en) * | 2007-04-23 | 2009-01-16 | Wyeth Corp | Methods of protein production using anti-senescence compounds |
ES2624185T3 (es) | 2007-04-26 | 2017-07-13 | Chugai Seiyaku Kabushiki Kaisha | Método de cultivo celular que utiliza un medio enriquecido con aminoácidos |
EP2188371B1 (en) | 2007-08-09 | 2017-12-20 | Wyeth LLC | Use of perfusion to enhance production of fed-batch cell culture in bioreactors |
US8319819B2 (en) | 2008-03-26 | 2012-11-27 | Cisco Technology, Inc. | Virtual round-table videoconference |
AU2009236187B2 (en) * | 2008-04-17 | 2012-08-02 | Wyeth Llc | Methods for enhanced production of bone morphogenetic proteins |
MX347112B (es) | 2008-09-15 | 2017-04-12 | Genentech Inc | Composiciones y metodos para regular osmolaridad celular. |
US8694658B2 (en) | 2008-09-19 | 2014-04-08 | Cisco Technology, Inc. | System and method for enabling communication sessions in a network environment |
NZ592097A (en) | 2008-10-20 | 2013-01-25 | Abbott Lab | Viral inactivation during purification of il-12 and il-18 antibodies |
NZ592095A (en) | 2008-10-20 | 2013-01-25 | Abbott Lab | Isolation and purification of il-12 and tnf-alpha antibodies using protein a affinity chromatography |
US8580554B2 (en) | 2009-07-31 | 2013-11-12 | Baxter International Inc. | Method of producing a polypeptide or virus of interest in a continuous cell culture |
PT2464725T (pt) * | 2009-08-11 | 2020-05-21 | Hoffmann La Roche | Produção de proteínas em meios de cultura celular isentos de glutamina |
GB0917647D0 (en) * | 2009-10-08 | 2009-11-25 | Glaxosmithkline Biolog Sa | Expression system |
RU2012134366A (ru) * | 2010-01-13 | 2014-02-20 | ЭйПиТи ТЕРАПЬЮТИКС, ИНК. | Терапевтические конструкции апиразы, средства на основе апиразы и способы получения |
US20110262965A1 (en) | 2010-04-23 | 2011-10-27 | Life Technologies Corporation | Cell culture medium comprising small peptides |
CA2797356C (en) * | 2010-04-26 | 2020-12-29 | Novartis Ag | Improved cell culture medium |
SG185014A1 (en) | 2010-04-26 | 2012-11-29 | Novartis Ag | Improved cell cultivation process |
AU2011246504B2 (en) | 2010-04-26 | 2013-09-26 | Novartis Ag | Improved cell culture medium |
AU2011274467B2 (en) * | 2010-07-08 | 2015-01-15 | Takeda Pharmaceutical Company Limited | Method of producing recombinant high molecular weight vWF in cell culture |
WO2012019160A1 (en) | 2010-08-05 | 2012-02-09 | Amgen Inc. | Dipeptides to enhance yield and viability from cell cultures |
WO2012023085A1 (en) | 2010-08-20 | 2012-02-23 | Wyeth Llc | Cell culture of growth factor-free adapted cells |
CN102382794B (zh) * | 2010-09-01 | 2013-09-18 | 山东新时代药业有限公司 | 一种哺乳动物细胞的灌流培养方法 |
US8599865B2 (en) | 2010-10-26 | 2013-12-03 | Cisco Technology, Inc. | System and method for provisioning flows in a mobile network environment |
US9338394B2 (en) | 2010-11-15 | 2016-05-10 | Cisco Technology, Inc. | System and method for providing enhanced audio in a video environment |
US8730297B2 (en) | 2010-11-15 | 2014-05-20 | Cisco Technology, Inc. | System and method for providing camera functions in a video environment |
US9143725B2 (en) | 2010-11-15 | 2015-09-22 | Cisco Technology, Inc. | System and method for providing enhanced graphics in a video environment |
US9062106B2 (en) | 2011-04-27 | 2015-06-23 | Abbvie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
EP2702164B8 (en) | 2011-04-29 | 2016-03-16 | Biocon Research Limited | A method for reducing heterogeneity of antibodies and a process of producing the antibodies thereof |
IL310968A (en) * | 2011-07-01 | 2024-04-01 | Amgen Inc | Mammalian cell culture |
US8682087B2 (en) | 2011-12-19 | 2014-03-25 | Cisco Technology, Inc. | System and method for depth-guided image filtering in a video conference environment |
WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
US9150645B2 (en) | 2012-04-20 | 2015-10-06 | Abbvie, Inc. | Cell culture methods to reduce acidic species |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
US20130281355A1 (en) * | 2012-04-24 | 2013-10-24 | Genentech, Inc. | Cell culture compositions and methods for polypeptide production |
WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
AU2013309506A1 (en) | 2012-09-02 | 2015-03-12 | Abbvie Inc. | Methods to control protein heterogeneity |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
SG11201507230PA (en) | 2013-03-12 | 2015-10-29 | Abbvie Inc | Human antibodies that bind human tnf-alpha and methods of preparing the same |
WO2014159579A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE |
US9217168B2 (en) | 2013-03-14 | 2015-12-22 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
CN105431454A (zh) * | 2013-07-06 | 2016-03-23 | 卡迪拉保健有限公司 | 用于生产单克隆抗体的改进方法 |
EP3052640A2 (en) | 2013-10-04 | 2016-08-10 | AbbVie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
US11390663B2 (en) * | 2013-10-11 | 2022-07-19 | Regeneron Pharmaceuticals, Inc. | Metabolically optimized cell culture |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
EP3083933A1 (en) | 2013-12-20 | 2016-10-26 | Biogen MA Inc. | Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality |
SI3110961T1 (sl) | 2014-02-27 | 2020-03-31 | F. Hoffmann-La Roche Ag | Modulacija rasti celic in glikozilacije pri rekombinantni proizvodnji glikoproteina |
EP3119876A1 (en) | 2014-03-19 | 2017-01-25 | Pfizer Inc. | Method of cell culture |
TW202246486A (zh) * | 2014-06-09 | 2022-12-01 | 美商健臻公司 | 種子罐培養法(seed train processes)及其用途 |
PL3227454T3 (pl) | 2014-12-01 | 2020-07-27 | Amgen Inc. | Sposób manipulowania poziomem zawartości glikanów w glikoproteinie |
EP4148121A3 (en) * | 2015-05-29 | 2023-06-07 | Boehringer Ingelheim International GmbH | Cell-controlled perfusion in continuous culture |
TW202340452A (zh) | 2015-08-04 | 2023-10-16 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
CA3214798A1 (en) | 2015-09-23 | 2017-03-30 | Pfizer Inc. | Cells and method of cell culture |
BR112018008864A8 (pt) | 2015-11-17 | 2019-02-26 | Pfizer | meios e métodos de fermentação para a produção de polissacarídeos em uma cultura de células bacterianas |
SG11201808356UA (en) * | 2016-04-05 | 2018-10-30 | Pfizer | Cell culture process |
EP3372670B1 (en) * | 2017-03-09 | 2019-02-27 | Evonik Technochemie GmbH | Culture media comprising n-acyl-x-glutamine dipeptides |
KR102190790B1 (ko) * | 2018-10-19 | 2020-12-15 | 주식회사 프로젠 | 변형된 egf 단백질의 생산 방법 |
US11339197B2 (en) | 2017-10-23 | 2022-05-24 | Progen Co., Ltd. | Modified EGF protein, production method therefor, and use thereof |
CN111406112A (zh) * | 2017-11-30 | 2020-07-10 | 豪夫迈·罗氏有限公司 | 用于培养哺乳动物细胞的工艺 |
EP3788076A1 (en) | 2018-05-01 | 2021-03-10 | Amgen Inc. | Antibodies with modulated glycan profiles |
BR112021008879A2 (pt) | 2018-11-13 | 2021-10-26 | Janssen Biotech, Inc. | Controle de oligometais durante a produção de anticorpos anti-cd38 |
WO2020115655A1 (en) | 2018-12-06 | 2020-06-11 | Pfizer Inc. | Cells with reduced inhibitor production and methods of use thereof |
CN113025648B (zh) * | 2019-12-09 | 2023-06-02 | 广东菲鹏制药股份有限公司 | Expi293细胞瞬时表达目标蛋白的方法及其应用 |
MX2023002417A (es) | 2020-08-31 | 2023-03-22 | Regeneron Pharma | Estrategias de suministro de asparagina para mejorar el rendimiento del cultivo celular y mitigar las variantes de secuencia de asparagina. |
JP2022060169A (ja) | 2020-10-02 | 2022-04-14 | ファイザー・インク | Rsv fタンパク質生産のための細胞培養工程 |
CN116761880A (zh) | 2021-01-20 | 2023-09-15 | 瑞泽恩制药公司 | 改进细胞培养物中的蛋白质滴度的方法 |
JP2022184798A (ja) | 2021-06-01 | 2022-12-13 | ファイザー・インク | sFGFR3ポリペプチドを生産するための細胞培養方法 |
KR20240090312A (ko) | 2021-10-07 | 2024-06-21 | 리제너론 파아마슈티컬스, 인크. | Ph 미터 보정 및 교정 |
CA3230984A1 (en) | 2021-10-07 | 2023-04-13 | Ross BROWNE | Systems and methods of ph modeling and control |
WO2023167855A1 (en) | 2022-03-02 | 2023-09-07 | Regeneron Pharmaceuticals, Inc. | Manufacturing process for high titer antibody |
US20240010709A1 (en) | 2022-05-25 | 2024-01-11 | Genentech, Inc. | Methods for preparing mammalian cells for perfusion cell culture |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US5672502A (en) * | 1985-06-28 | 1997-09-30 | Celltech Therapeutics Limited | Animal cell culture |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US6048728A (en) | 1988-09-23 | 2000-04-11 | Chiron Corporation | Cell culture medium for enhanced cell growth, culture longevity, and product expression |
US6291159B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for producing polymers having a preselected activity |
US5395760A (en) | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
NZ235148A (en) | 1989-09-05 | 1991-12-23 | Immunex Corp | Tumour necrosis factor receptor protein and dna sequences |
US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
JPH0396383A (ja) | 1989-09-08 | 1991-04-22 | Riso Kagaku Corp | 画像形成装置 |
DE59010908D1 (de) | 1989-09-12 | 2000-08-10 | Hoffmann La Roche | TNF-bindende Proteine |
ATE168416T1 (de) | 1989-10-05 | 1998-08-15 | Optein Inc | Zellfreie synthese und isolierung von genen und polypeptiden |
US6657103B1 (en) | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5538983A (en) * | 1990-05-16 | 1996-07-23 | The Rockefeller University | Method of treating amyloidosis by modulation of calcium |
US5156964A (en) | 1990-08-16 | 1992-10-20 | Cetus Corporation | Methods for adapting cells for increased product production through exposure to ammonia |
US5122469A (en) * | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
GB9021679D0 (en) | 1990-10-05 | 1990-11-21 | Gorman Scott David | Antibody preparation |
GB9022545D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Culture medium |
GB2251249B (en) | 1990-12-28 | 1995-06-21 | Mogam Biotech Res Inst | High-density medium for animal cell culture |
GB9118664D0 (en) | 1991-08-30 | 1991-10-16 | Celltech Ltd | Cell culture |
US5447851B1 (en) * | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
US6607884B1 (en) * | 1993-03-19 | 2003-08-19 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-8 |
DE4313620A1 (de) * | 1993-04-26 | 1994-10-27 | Biotechnolog Forschung Gmbh | Hamsterzellinien und Verfahren zur Glykoproteingewinnung |
JP3504963B2 (ja) | 1993-10-22 | 2004-03-08 | 智靖 羅 | 抗ヒト高親和性IgE受容体モノクローナル抗体に係るアミノ酸配列をコードするDNA断片 |
US6310185B1 (en) | 1994-03-08 | 2001-10-30 | Memorial Sloan Kettering Cancer Center | Recombinant human anti-Lewis Y antibodies |
US5856179A (en) | 1994-03-10 | 1999-01-05 | Genentech, Inc. | Polypeptide production in animal cell culture |
US5589154A (en) * | 1994-11-22 | 1996-12-31 | Rutgers, The State University Of New Jersey | Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease |
US6656466B1 (en) * | 1995-06-06 | 2003-12-02 | Genetech, Inc. | Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition |
US5705364A (en) | 1995-06-06 | 1998-01-06 | Genentech, Inc. | Mammalian cell culture process |
US5721121A (en) * | 1995-06-06 | 1998-02-24 | Genentech, Inc. | Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein |
JP4306813B2 (ja) * | 1995-09-19 | 2009-08-05 | アスビオファーマ株式会社 | 動物細胞の新規培養方法 |
US20020012991A1 (en) | 1997-04-07 | 2002-01-31 | Florence Chua Nee Ho Kit Fong | Cell culture media for enhanced protein production |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
CA2354862A1 (en) | 1998-10-19 | 2000-04-27 | Yeda Research And Development Co. Ltd. | Treatment of systemic lupus erythematosus by down-regulating the autoimmune response to autoantigens |
TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
TW200526779A (en) | 2001-02-08 | 2005-08-16 | Wyeth Corp | Modified and stabilized GDF propeptides and uses thereof |
ATE409047T1 (de) | 2001-04-30 | 2008-10-15 | Lilly Co Eli | Humanisierte antikörper |
AU2002258808A1 (en) | 2001-04-30 | 2002-11-11 | Eli Lilly And Company | Humanized antibodies |
EP1404813A4 (en) | 2001-06-13 | 2004-11-24 | Genentech Inc | METHOD FOR CULTIVATING ANIMAL CELLS AND POLYPEPTIDE PRODUCTION IN ANIMAL CELLS |
US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
CA2476654A1 (en) | 2002-02-21 | 2003-09-04 | Wyeth | Follistatin domain containing proteins |
BR0307907A2 (pt) | 2002-02-21 | 2011-07-05 | Wyeth Corp | gasp1: proteìna contendo domìnio de folistatina |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
LT3127553T (lt) | 2002-05-02 | 2022-04-11 | Wyeth Holdings Llc | Kalicheamicino darinio ir nešiklio konjugatai |
US6924124B1 (en) | 2002-08-23 | 2005-08-02 | Immunex Corporation | Feeding strategies for cell culture |
US7261893B2 (en) * | 2002-10-22 | 2007-08-28 | Wyeth | Neutralizing antibodies against GDF-8 and uses therefor |
US20040223966A1 (en) | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
US7335491B2 (en) | 2004-08-27 | 2008-02-26 | Wyeth Research Ireland Limited | Production of anti-abeta |
US7294484B2 (en) | 2004-08-27 | 2007-11-13 | Wyeth Research Ireland Limited | Production of polypeptides |
US7300773B2 (en) | 2004-08-27 | 2007-11-27 | Wyeth Research Ireland Limited | Production of TNFR-Ig |
-
2005
- 2005-08-25 US US11/213,308 patent/US7294484B2/en active Active
- 2005-08-25 TW TW94129070A patent/TWI384069B/zh not_active IP Right Cessation
- 2005-08-26 SG SG2013041199A patent/SG190674A1/en unknown
- 2005-08-26 JP JP2007530166A patent/JP4864892B2/ja active Active
- 2005-08-26 WO PCT/US2005/030437 patent/WO2006026445A1/en active Application Filing
- 2005-08-26 AU AU2005280034A patent/AU2005280034B2/en active Active
- 2005-08-26 KR KR1020117006936A patent/KR20110036780A/ko not_active Application Discontinuation
- 2005-08-26 KR KR1020077004807A patent/KR101158447B1/ko active IP Right Grant
- 2005-08-26 CN CN2005800368991A patent/CN101048511B/zh not_active Expired - Fee Related
- 2005-08-26 CA CA 2578141 patent/CA2578141C/en active Active
- 2005-08-26 ES ES05792494T patent/ES2628012T3/es active Active
- 2005-08-26 EP EP05792494.6A patent/EP1789571B1/en not_active Revoked
- 2005-08-26 CN CN201210189727.XA patent/CN102827905B/zh not_active Expired - Fee Related
- 2005-08-26 SG SG200907913-8A patent/SG158092A1/en unknown
- 2005-08-26 EP EP11156236.9A patent/EP2357250B1/en not_active Revoked
- 2005-08-26 AR ARP050103594 patent/AR051017A1/es not_active Application Discontinuation
- 2005-08-26 MX MX2007002380A patent/MX2007002380A/es active IP Right Grant
- 2005-08-26 BR BRPI0514703-4A patent/BRPI0514703A/pt not_active Application Discontinuation
-
2007
- 2007-02-27 IL IL181589A patent/IL181589A0/en unknown
- 2007-02-27 EG EGNA2007000223 patent/EG26462A/en active
- 2007-03-16 CR CR8997A patent/CR8997A/es unknown
- 2007-03-26 ZA ZA2007/02483A patent/ZA200702483B/en unknown
- 2007-03-26 NO NO20071572A patent/NO342433B1/no not_active IP Right Cessation
- 2007-03-27 EC ECSP077353 patent/ECSP077353A/es unknown
-
2012
- 2012-06-14 AR ARP120102112 patent/AR086932A2/es not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2007002380A (es) | Produccion de polipeptidos. | |
TW200619388A (en) | Production of TNFR-lg | |
TW200615379A (en) | Production of α-abeta | |
BRPI0516176A (pt) | polipeptìdeo, dna, microorganismo, e, processo para produzir l-arginina, l-ornitina ou l-citrulina | |
MX2008016047A (es) | Plantas que tienen rasgos mejorados relacionados con el crecimiento y un metodo para obtener las mismas. | |
MY185040A (en) | Cell culture improvements | |
IN2015DN02553A (es) | ||
MX2009011362A (es) | Uso de temperatura baja y/o ph bajo en el cultivo celular. | |
IL190796A (en) | Composition containing nucleic acid encoded by anti-osteoclastogenic protein | |
MX2010002753A (es) | Plantas que tienen rasgos aumentados relacionados con el rendimiento y un metodo para obtenerlas. | |
EA201001435A1 (ru) | Клетка, ферментирующая сахар-пентозу | |
CA2783820C (en) | Protease variants | |
UA92157C2 (ru) | Способ продуцирования гормона роста | |
ATE512229T1 (de) | Neuer vektor und expressionszelllinie zur massenproduktion von rekombinantem protein sowie verfahren zur produktion von rekombinantem protein damit | |
EA201001881A1 (ru) | Пролинспецифичная протеаза из penicillium chrysogenum | |
GB2439039A (en) | Identification of a sterol acyltransferase gene | |
TW200638944A (en) | Recombinant enterovirus 71 neutralizing antibodies and use thereof | |
WO2007013358A3 (en) | Vivit polypeptides, therapeutic agent comprising the same, and method of screening for anti-cancer agent | |
WO2008126783A1 (ja) | ジペプチドの製造法 | |
WO2010115634A8 (en) | Method for improved single cell cloning | |
WO2007071578A3 (de) | Verfahren zur herstellung von 5 -norbornen-2-carbonsäure aus 5-norbornen-2-carbonitril unter verwendung einer arylacetonitrilase | |
Rotaru et al. | frontiers Frontiers in Microbiology ORIGINAL RESEARCH published: 10 May 2022 | |
DE69923595D1 (de) | Herstellung von proteinen | |
EP1561810A3 (en) | Mutant microorganism and method for producing peptide using the same | |
WO2007079558A3 (en) | Proline-rich peptides, pharmaceutical composition, use of one or more peptides and method of treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration | ||
GB | Transfer or rights |